Imo Ocata is far from in the driver's seat here and other possible suitors know it.
It is one thing for Ocata to have a finished marketable product or on the verge of having one.
That is far from the case here;by the company's own admission, it is a number of years away even if and a big if if they get FDA approval.
Other companies/suitors realize this and know that Ocata hasn't "stemcelled" a money tree either and could run out of money before they do get to the marketing stage.
Toss in the scandal ridden reputation of ACTC/Ocata, and frankly you can't blame any other company for sticking its neck out-better to wait, let Ocata struggle and then move in for the kill when it is even more evident than it is now that Ocata can no longer continue on its own.
By my way of thinking PW no matter what his motivation is, and Lanza and the BOD, have already admitted by implication by accepting the $8.50 from Astellas that the company can't get it done on its own.
Thus from my point of view, if Astellas doesn't get the 50.1% needed and walks away, the other possible suitors rather than getting into a bidding war, are simply going to sit back and wait for Ocata to run out of money to continue and then move in for the spoils.
I also believe and have believed for a long time that BP has the FDA in their pocket, and thus that the latter will make it quite difficult for Ocata to succeed even if they should get needed financing.
Further, if my scenario is correct, the stock price will suffer badly and the $8.50 offer will seem like a dream in retrospect-most importantly investor's who didn't take the $8.50 will suffer not only by not taking the $8.50 per se but because that $8.50 will not be able to be deployed in the market with better investments.
